CRISPR Therapeutics AG. (3/2/17). "Press Release: CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference". Basel & Cambridge, MA.

	Organisation	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Organisation 2	Barclays Capital
	Group	Barclays (Group)
	Product	Barclays Global Healthcare Conference 2017 Miami
	Product 2	CRISPR gene editing technology
	Index term	CRISPR Therapeutics–Barclays: investor conference, 201703 supply service CRISPR Therapeutics presents at Barclays Global Healthcare Conference
	Person	Novak, Rodger (CRISPR Therapeutics 201712– Board Chairman 2013–201711 CEO + Co-Founder before Sanofi + Nabriva GmbH)
	Person 2	Paganelli, Jennifer (W2O Group 201703)

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the Annual Barclays Global Healthcare Conference on Thursday, March 16th at the Loews Miami Beach Hotel, Miami, FL.

Event: Annual Barclays Global Healthcare Conference

Date: Thursday, March 16th

Time: 8:00 AM ET

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the Company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.

MEDIA CONTACTS:
Jennifer Paganelli
W2O Group for CRISPR
347-658-8290
jpaganelli@w2ogroup.com

INVESTOR CONTACT:
Chris Brinzey
Westwicke Partners for CRISPR
339-970-2843
chris.brinzey@westwicke.com

Record changed: 2023-06-05